Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced that the